The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Jan 2, 2018 • 49min
Ep9: Bob More
Bob More on biotech venture capital
Dec 20, 2017 • 1h 2min
Ep8: BioMarin History
Daniel Levine & Dan Maher discuss their book "A Rare Breed."
Dec 5, 2017 • 58min
Ep7: Steve Graham
Steve Graham on racism in Corporate America.
Nov 29, 2017 • 60min
Ep6: Steve Holtzman
Ep6: Steve Holtzman of Decibel Therapeutics on political activism among biotech CEOs.
Nov 8, 2017 • 47min
Ep5: Elias Zerhouni
Elias Zerhouni, president of R&D at Sanofi, on immigration in science and the importance of government science funding.
Oct 24, 2017 • 57min
Ep4: Richard Pops
Alkermes CEO Richard Pops on fighting the opioid painkiller crisis.
Oct 10, 2017 • 58min
Ep3: George Yancopoulos
Interview with Regeneron president and CSO George Yancopoulos
Sep 27, 2017 • 57min
Ep2: Katrine Bosley
Ep. 2 of The Long Run With Luke Timmerman. Interview with Katrine Bosley, CEO of Editas Medicine.

Sep 13, 2017 • 59min
Ep1: John Maraganore
Ep. 1 of The Long Run, a biotech podcast with Luke Timmerman. Conversation with Alnylam Pharmaceuticals CEO John Maraganore.


